Accessibility Menu
Rani Therapeutics logo

Rani Therapeutics

(NASDAQ) RANI

Current Price$0.78
Market Cap$86.36M
Since IPO (2021)-93%
5 YearN/A
1 Year+50%
1 Month-14%

Rani Therapeutics Financials at a Glance

Market Cap

$86.36M

Revenue (TTM)

$3.17M

Net Income (TTM)

-$29.44M

EPS (TTM)

-$0.41

P/E Ratio

-1.88

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.78

Volume

40,394.045

Open

$0.78

Previous Close

$0.77

Daily Range

$0.78 - $0.78

52-Week Range

$0.39 - $3.87

Estimated Earnings Date

Aug 6, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rani Therapeutics

Industry

Pharmaceuticals

Employees

71

CEO

Talat Imran

Headquarters

San Jose, CA 95131, US

RANI Financials

Key Financial Metrics (TTM)

Gross Margin

94.92%

Operating Margin

-1092.96%

Net Income Margin

-929.06%

Return on Equity

-245.45%

Return on Capital

-102.63%

Return on Assets

-56.75%

Earnings Yield

-53.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$86.36M

Shares Outstanding

112.39M

Volume

40.39K

Avg. Volume

891.36K

Financials (TTM)

Gross Profit

$3.01M

Operating Income

-$34.64M

EBITDA

-$33.38M

Operating Cash Flow

-$17.06M

Capital Expenditure

-$52.00K

Free Cash Flow

-$17.11M

Cash & ST Invst.

$43.40M

Total Debt

$3.94M

Rani Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.71M

+893.0%

Gross Profit

$1.55M

+799.4%

Gross Margin

90.57%

N/A

Market Cap

$86.36M

N/A

Market Cap/Employee

$822.47K

N/A

Employees

105

N/A

Net Income

-$7.03M

+3.2%

EBITDA

-$7.77M

+32.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$43.40M

+173.8%

Total Debt

$3.94M

-84.6%

Accounts Receivable

$2.11M

+252.2%

Inventory

$0.00

N/A

Long Term Debt

$2.48M

-73.4%

Short Term Debt

$1.46M

-91.1%

Return on Assets

-56.75%

N/A

Return on Invested Capital

-91.09%

N/A

Free Cash Flow

-$6.51M

+20.6%

Operating Cash Flow

-$6.50M

+20.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRDFCardiff Oncology, Inc.
$1.30+0.39%
ELTXElicio Therapeutics, Inc.
$3.55-31.03%
MISTMilestone Pharmaceuticals Inc.
$1.35+1.89%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$9.36+3.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.62+0.01%
CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF
$5.54+0.10%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$12.76+0.05%
NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF
$4.94+0.00%

Questions About RANI

What is the current price of Rani Therapeutics?

Rani Therapeutics is trading at $0.78 per share.

What is the 52-week range for Rani Therapeutics?

Over the past 52 weeks, Rani Therapeutics has traded between $0.39 and $3.87.

How much debt does Rani Therapeutics have?

As of the most recent reporting period, Rani Therapeutics reported total debt of $3.94M.

How much cash does Rani Therapeutics have on hand?

Rani Therapeutics reported $9.84M in cash and cash equivalents in its most recent financial results.

What is Rani Therapeutics’s dividend yield?

Rani Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.